A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas

What is the purpose of this trial?

The purpose of this study is to assess the safety and tolerability of escalating doses of TRQ15-01 in patients with relapsed/refractory/metastatic or locally-advanced solid tumors and lymphomas.



Torque Therapeutics

Start Date: 05/03/2019

End Date: 09/01/2021

Last Updated: 05/06/2019

Study HIC#: 2000024303

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247
neta.shanwetterlevit@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Harriet Kluger

Principal Investigator

Sub-Investigators